AXDX - Accelerate Diagnostics Price to Earnings Adjusted for Growth Rate

Accelerate Diagnostics attracts microbiology experts through patent bonuses and RSUs. Stable demand for sepsis tests provides personnel with long-term job security. The PEG ratio on the chart demonstrates capital density, with the latest parameter standing at 0.00. Low geopolitical risks and the humanitarian status of biomedicine make the business's operating environment highly resilient to global conflicts.

Accelerate Diagnostics, Inc (AXDX): PEG Multiple from 07/04/2022 to 05/24/2025

Analytical breakdowns for Accelerate Diagnostics (AXDX)

- current price and projected stock value:

Price Chart Accelerate Diagnostics Inc.|AXDX - Consensus Target

- market capitalization statistics:

Market Value Accelerate Diagnostics, Inc|AXDX - Total Company Value

- shareholders' equity book value data:

Net Assets per Share Accelerate Diagnostics|AXDX - Book Capitalization|Market Capitalization to Book Value acceleratediagnostics.com|AXDX - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

Total Debt to Capital Coefficient Accelerate Diagnostics|AXDX - Long-Term Debt to Capital|Short-Term Debt to Capital acceleratediagnostics.com|AXDX - Company Aggregate Debts|Debt to Book Value Accelerate Diagnostics, Inc|AXDX - Company Long-Term Debts|Company Current Liabilities Accelerate Diagnostics|Immediate Liquidity acceleratediagnostics.com

- net income and valuation ratios data:

AXDX - Company Net Income|Expected Profit Accelerate Diagnostics|AXDX - P/E Multiple|Projected Price to Earnings Ratio Accelerate Diagnostics Inc|AXDX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Accelerate Diagnostics, Inc|AXDX - Operating profit EBITDA|Net earnings per share (EPS TTM) Accelerate Diagnostics|AXDX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months acceleratediagnostics.com|AXDX - Earnings growth in current year|Expected net earnings per share growth next year Accelerate Diagnostics

General company analysis:AXDX (Accelerate Diagnostics Inc.)

Core merchandise of Accelerate Diagnostics

The implementation of rapid infection diagnostic systems through clinic partnerships scales the operational efficiency of Accelerate Diagnostics (AXDX), establishing a foundation for business expansion. This PEG ratio compares the stock's market value with its earnings per share growth: values below one signal that the asset is undervalued relative to its growth rate, confirming the potential for sustainable price appreciation.

Competing companies